492
Views
11
CrossRef citations to date
0
Altmetric
Drug Evaluation

Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington’s disease: a review of clinical trial data

, &
Pages 2209-2221 | Received 01 May 2019, Accepted 26 Sep 2019, Published online: 15 Oct 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Thomas Kinfe, Alessandro Del Vecchio, Martin Nüssel, Yining Zhao, Andreas Stadlbauer & Michael Buchfelder. (2022) Deep brain stimulation and stereotactic-assisted brain graft injection targeting fronto-striatal circuits for Huntington’s disease: an update. Expert Review of Neurotherapeutics 22:9, pages 781-788.
Read now
Christian Cheng, Nicholas Brownstone & John Koo. (2022) Treatment of tardive dyskinesia: a review and update for dermatologists managing delusions of parasitosis. Journal of Dermatological Treatment 33:3, pages 1319-1323.
Read now

Articles from other publishers (9)

Xiao-Liang Xu, Wen Zhang & Guo-Wu Rao. (2023) Clinical Application and Synthesis Methods of Deuterated Drugs. Current Medicinal Chemistry 30:36, pages 4096-4129.
Crossref
Frank Schneider, Borje Darpo, Pippa S. Loupe, Hongqi Xue, Helena Knebel, Maria Gutierrez, Mark Forrest Gordon & Laura Rabinovich‐Guilatt. (2022) Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration‐QTc Analysis. Clinical Pharmacology in Drug Development 12:1, pages 94-106.
Crossref
Melissa Talita Wiprich, Stefani Altenhofen, Darlan Gusso, Rafaela da Rosa Vasques, Rodrigo Zanandrea, Luiza Wilges Kist, Mauricio Reis Bogo & Carla Denise Bonan. (2022) Modulation of adenosine signaling reverses 3-nitropropionic acid-induced bradykinesia and memory impairment in adult zebrafish. Progress in Neuro-Psychopharmacology and Biological Psychiatry, pages 110602.
Crossref
Harshit Gupta, Wil Perkins, Cain Stark, Sathya Kikkeri, Juyeon Kakazu, Adam D. Kaye & Alan D. Kaye. (2022) deutetrabenazine for the treatment of chorea associated with Huntington’s disease. Health Psychology Research 10:5.
Crossref
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry 1 224 .
Chih-Wei Tung, Pin-Yu Huang, Siew Chin Chan, Pei-Hsun Cheng & Shang-Hsun Yang. (2021) The regulatory roles of microRNAs toward pathogenesis and treatments in Huntington's disease. Journal of Biomedical Science 28:1.
Crossref
Frank Schneider, David Stamler, Margaret Bradbury, Pippa S. Loupe, Edward Hellriegel, Donna S. Cox, Juha‐Matti Savola, Mark Forrest Gordon & Laura Rabinovich‐Guilatt. (2020) Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect. Clinical Pharmacology in Drug Development 10:6, pages 647-659.
Crossref
Zeynep Tufekcioglu, Basar Bilgic, Hasmet Hanagasi & Murat Emre. 2021. Management of Patients with Dementia. Management of Patients with Dementia 201 227 .
Ryoma Morigaki, Jannifer H. Lee, Tomoko Yoshida, Christian Wüthrich, Dan Hu, Jill R. Crittenden, Alexander Friedman, Yasuo Kubota & Ann M. Graybiel. (2020) Spatiotemporal Up-Regulation of Mu Opioid Receptor 1 in Striatum of Mouse Model of Huntington’s Disease Differentially Affecting Caudal and Striosomal Regions. Frontiers in Neuroanatomy 14.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.